Abstract:There is a continuing, urgent need for an ophthalmic (eye) drop for the clinical therapy of age-related macular degeneration (AMD), a leading cause of blindness. Here, we report the first formulation of an eye drop that is effective via autophagy for AMD treatment. This eye drop is based on a single natural product derivative (ACD), which is an amphiphilic molecule containing a 6-aminohexanoate group (H2N(CH2)5COO−). We demonstrate that this eye drop reverses the abnormal angiogenesis induced in a primate model of AMD that has the pathological characteristics close to that of human AMD. The ACD molecule was self-assembled in an aqueous environment leading to nanoparticles (NPs) about 9.0 nm in diameter. These NPs were encapsulated in calcium alginate hydrogel. The resulting eye drop effectively slowed the release of ACD and displayed extended release periods in both simulated blood (pH 7.4) and inflammatory (pH 5.2) environments. We show that the eye drop penetrated both the corneal and blood–eye barriers and reached the fundus. With low cellular toxicity, the drop targeted S1,25D3-membrane-associated rapid response steroid-binding protein (1,25D3-MARRS) promoting autophagy in a dose-dependent manner. In addition, the drop inhibited cell migration and tubular formation. On the other hand, when protein 1,25D3-MARRS was knocked down, the eye drop did not exhibit such inhibition functionalities. Our study indicates that the 6-aminohexanoate group on self-assembled NPs encapsulated in hydrogel leads to the positive in vivo outcomes. The present formulation offers a promising approach for clinical treatment of human AMD.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c17296?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c17296</a>.Experimental methods; inflammatory infiltration prevented in the AMD monkey model (Figure S1-1); comparison of the antichoroidal neovascularization activity (CNV) (Figure S1-2); estimation of the eye injury for the two groups (shown in <a class="internalNav" href="#fig1">Figure </a><a class="internalNav" href="#fig1">1</a>) (Table S1); preparation and characterization of eye drops (Figure S2-1); measurements of ACD nanoparticle size up to 21 days (Figure S2-2); exploration of the self-assembly of five Dio derivatives in water (Figure S2-3); investigation of the self-assembly of ACD in water (Figure S2-4); examination of the self-assembly of ACD in water containing five amounts of β-cyclodextrin (Figure S2-5); comparison of the release of ACD shown in <a class="internalNav" href="#fig3">Figure </a><a class="internalNav" href="#fig3">3</a> (Figure S3); pharmacokinetic studies of ACD in rats' plasma (Figure S4); summary of pharmacokinetic data for plasma ACD in rats (Table S2); optical microscope images for <a class="internalNav" href="#fig5">Figure </a><a class="internalNav" href="#fig5">5</a>a (Figure S5-1); in vivo toxicity study (Figure S5-2); exploration of the amount effect of EDTA calcium (Figure S5-3); quantitative analysis of LC3II/LC3I for <a class="internalNav" href="#fig6">Figure </a><a class="internalNav" href="#fig6">6</a>a Western blots (Figure S6-1); RPE cell explored for 1,25D3-MARRS and autophagy (Figure S6-2); quantitative analysis for <a class="internalNav" href="#fig7">Figures </a><a class="internalNav" href="#fig7">7</a>b,c (Figure S7); and note on the design and preparation of ACD eye drops (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c17296/suppl_file/am0c17296_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Eyedrop delivery of therapeutic proteins with zwitterionic polymers to treat dry age-related macular degeneration

Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment

Ophthalmic Drops with Nanoparticles Derived from a Natural Product for Treating Age-Related Macular Degeneration

Hydrogel eye drops as a non-invasive drug carrier for topical enhanced Adalimumab permeation and highly efficient uveitis treatment

A hyaluronic acid-modified cyclodextrin self-assembly system for the delivery of β-carotene in the treatment of dry eye disease

Synthesis and Evaluation of a Nanoglobular Dendrimer 5-Aminosalicylic Acid Conjugate with a Hydrolyzable Schiff Base Spacer for Treating Retinal Degeneration

Ultra-small-size Astragaloside-IV loaded lipid nanocapsules eye drops for the effective management of dry age-related macular degeneration

A Sustainable Retinal Drug Codelivery for Boosting Therapeutic Efficacy in wAMD: Unveiling Multifaceted Evidence and Synergistic Mechanisms

Nanomicelle‐Assisted Targeted Ocular Delivery with Enhanced Antiinflammatory Efficacy in Vivo

Injectable Anti‐inflammatory Supramolecular Nanofiber Hydrogel to Promote Anti‐VEGF Therapy in Age‐Related Macular Degeneration Treatment

Coaxial Electrospray of Ranibizumab-Loaded Microparticles for Sustained Release of Anti-VEGF Therapies.

A Single Molecule Carrier for Ocular Posterior Segment Diseases

Mucoadhesive, antioxidant, and lubricant catechol-functionalized poly(phosphobetaine) as biomaterial nanotherapeutics for treating ocular dryness

Neovascularization-directed bionic eye drops for noninvasive renovation of age-related macular degeneration

Triamcinolone acetonide-chitosan coated liposomes efficiently treated retinal edema as eye drops.

Emerging Co-Assembled and Sustained Released Natural Medicinal Nanoparticles for Multitarget Therapy of Choroidal Neovascularization

Rational design of mixed nanomicelle eye drops with structural integrity investigation

Advanced nanomedicines for the treatment of age-related macular degeneration

Novel mPEG-CS-modified flexible liposomes-reinforced thermosensitive sol-gel reversible hydrogels for ocular delivery of multiple drugs with enhanced synergism

Targeted Long-term Noninvasive Treatment of Choroidal Neovascularization by Biodegradable Nanoparticles

Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery